The Effects of Exogenous Arachidonic Acid on Cyclooxygenase Activity and Isoform Expressed in Endothelial Cells

Main Article Content

Duangporn Plasen
Pravit Akarasereenont
Kitirat Techatraisak
Athiwat Thaworn
Sirikul Chotewuttakorn


Prostaglandin (PGs) have numerous cardiovascular and inflammatory effects. Cyclooxygenase (COX) is the first enzyme in the pathway in which arachidonic acid is converted to PGs, prostacyclin (PGI2) and thromboxane (TX) A2. PGI2 is the major COX metabolite released from endothelial cells which participating in inflammation, atherosclerosis, thrombosis, etcs. Endothelial cells can be activated by arachidonic acid (AA) and its metabolites. Here, we have investigated the effects of AA on the PGI2 released from human umbilical vein endothelial cell (HUVEC) by measuring the production of 6-keto-PGF1 (a stable metabolite of PGI2) in the supernatant at various arachidonic acid concentrations and variable times of AA incubation. We also studied the effects of AA on COX protein expressed in HUVEC. HUVEC was obtained from babies born to normal pregnancy and grown in T25 flasks with endothelial cell (EC) medium supplemented with I 0% fetal calf serum until confluent. The cells were then subcultured into 96-well culture plates, allowed to grow to confluent and replaced with fresh medium containing AA (0.1, 1, 10 and 20 μM). Cell were incubated at 37OC under 5 % CO2 concentration in the CO2-incubator for variable periods of times (5, 10, 20 and 30 minutes). After which time, 6-keto-PGF1 in the supernatant medium was measured by using enzyme immunoassay (EIA). The remained cells were extracted to detect COX protein expression using specific antibody to COX-I and COX-2. Cell respiration, an indication of cell viability, was assessed by the mitochondrial-dependent reduction of 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl tetrazolium bromide (MTT) to formazan. Either various concentrations (0.1-20 μM) or variable periods of times (5-30 minutes) of AA had any effect on cell viability. Control HUVEC without AA released undetectable amount of 6-keto-PGF1 (< 3 pg/ml). At various concentrations of AA, HUVEC activated with exogenous AA could release higher amount of 6-keto-PGF1 in a dose dependent manner. Interestingly, time of AA incubation did not affect the 6-keto-PGF1 production at lower doses of AA (0.1, 1 and 10 μM). However, the higher concentration of AA (20μM) was trend to produce the higher 6-keto-PGF1. Moreover, AA did not effect on COX protein expressed in HUVEC which were expressed COX-1 protein but not

COX-2 protein. Thus, exogenous AA can increase PGI2 released from HUVEC in a dose dependent manner but not time dependent. The increased PGI2 release from HUVEC was from COX-1 function.

Article Details

1999 Annual Meeting Abstracts/Lectures